Experience with Vildagliptin in Type 2 Diabetic Patients Fasting During Ramadan in France: Insights from the VERDI Study

Treatment adherence with vildagliptin compared to sulphonylurea as add-on to metformin in Muslim patients with type 2 diabetes mellitus fasting during Ramadan

(2013) W. Hanif et al.   CURRENT MEDICAL RESEARCH AND OPINION

Patient perspectives on type 2 diabetes and medicine use during Ramadan among Pakistanis in Denmark

(2013) Anna Mygind et al.   International Journal of Clinical Pharmacy

Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic study

(2012) S.R. Aravind et al.   CURRENT MEDICAL RESEARCH AND OPINION

Real-life comparison of DPP4-inhibitors with conventional oral antidiabetics as add-on therapy to metformin in elderly patients with type 2 diabetes: The HYPOCRAS study

(2012) A. Penfornis et al.   DIABETES & METABOLISM

Ramadan Prospective Diabetes Study: the role of drug dosage and timing alteration, active glucose monitoring and patient education

(2012) M. Y. Ahmedani et al.   DIABETIC MEDICINE

Pharmacological approaches to the management of type 2 diabetes in fasting adults during Ramadan

(2012) Mohamed AlMaatouq   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study

(2011) Mohamed Hassanein et al.   CURRENT MEDICAL RESEARCH AND OPINION

Hypoglycaemia in sulphonylurea-treated subjects with type 2 diabetes undergoing Ramadan fasting: a five-country observational study

(2011) S.R. Aravind et al.   CURRENT MEDICAL RESEARCH AND OPINION

Ramadan fasting with diabetes: An interview study of inpatients’ and general practitioners’ attitudes in the South of France

(2011) B. Gaborit et al.   DIABETES & METABOLISM

The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial

(2011) S. Al Sifri et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Minimizing the risk of hypoglycemia with vildagliptin: Clinical experience, mechanistic basis, and importance in type 2 diabetes management

(2011) Sylvie Dejager et al.   Diabetes Therapy

Recommendations for Management of Diabetes During Ramadan: Update 2010

(2010) M. Al-Arouj et al.   DIABETES CARE

Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study

(2010) D. R. Matthews et al.   DIABETES OBESITY & METABOLISM

Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trials

(2010) A. Schweizer et al.   DIABETES OBESITY & METABOLISM

Diabetes and fasting during Ramadan

(2010) Elaine Hui et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Ramadan Education and Awareness in Diabetes (READ) programme for Muslims with Type 2 diabetes who fast during Ramadan

(2010) V. Bravis et al.   DIABETIC MEDICINE

Maintenance of glycaemic control with the evening administration of a long acting sulphonylurea in male type 2 diabetic patients undertaking the Ramadan fast

(2010) A. H. Zargar et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy

(2009) E. Ferrannini et al.   DIABETES OBESITY & METABOLISM

Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan

(2009) D. Devendra et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Ramadan-focused education and awareness in type 2 diabetes

(2008) M. Hassanein et al.   DIABETOLOGIA